The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention

  • Juan Tamargo
    Department of Pharmacology, School of Medicine, Universidad Complutense, 28040, Madrid, Spain
    Search for articles by this author
  • José M. Castellano
    Centro Nacional de Investigaciones Cardiovasculares (CNIC) Carlos III, Madrid, Spain

    HM Hospitales, Hospital Universitario Montepríncipe, Madrid, Spain

    Mount Sinai Cardiovascular Institute, New York, USA
    Search for articles by this author
  • Valentín Fuster
    Corresponding author at: Mount Sinai Heart, One Gustave L. Levy Place, Box 1030 New York City, NY 10029. Tel.: 212.241.3852; fax: 212.423.9488
    Centro Nacional de Investigaciones Cardiovasculares (CNIC) Carlos III, Madrid, Spain

    Mount Sinai Cardiovascular Institute, New York, USA
    Search for articles by this author
      This paper is only available as a PDF. To read, Please Download here.


      During the last decade, there has been a tremendous effort to develop different cardiovascular polypills in response to the upsurge in global cardiovascular disease worldwide. The pharmacological development of such a strategy has proven to be extremely complex from a formulation standpoint. Not all drugs are suitable for use in a polypill because of potential drug incompatibilities between them. Candidate agents must be safe, well tolerated, effective, guideline recommended and physiochemically compatible with the other components of the pill.
      The Fuster-CNIC-Ferrer cardiovascular (CV) polypill has been found to be the first-in-class polypill to be approved and commercialized in Europe and Latinamerican Countries. In this article, we review the pharmacological properties of its three components, including the clinical evidence supporting their use in patients with established cardiovascular disease, their pharmacokinetic properties, adverse effects, drug interactions and contraindications.



        • Wald NJ
        • Law MR
        A strategy to reduce cardiovascular disease by more than 80%.
        BMJ. 2003; 326: 1419
        • Sanz G
        • Fuster V
        Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population.
        Nature Clin Prac Cardiovasc Med. 2009; 6: 101-110
        • Castellano JM
        • Sanz G
        • Fuster V
        Evolution of the polypill concept and ongoing clinical trials.
        Can J Cardiol. 2014; 30: 520-526
        • Castellano JM
        • Sanz G
        • Penalvo JL
        • Bansilal S
        • Fernandez-Ortiz A
        • Alvarez L
        • et al.
        A polypill strategy to improve adherence: results from the FOCUS project.
        J Am Coll Cardiol. 2014; 64: 2071-2082
        • Smith SC
        • Benjamin EJ
        • Bonow RO
        • Braun LT
        • Creager MA
        • Franklin BA
        • et al.
        AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association.
        J Am Coll Cardiol. 2011; 58: 2432-2446
        • Perk J
        • De Backer G
        • Gohlke H
        • Graham I
        • Reiner Ž
        • Verschuren M
        • et al.
        European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR).
        Eur Heart J. 2012; : ehs092
        • Steg PG
        • James SK
        • Atar D
        • Badano LP
        • Lundqvist CB
        • Borger MA
        • et al.
        ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.
        Eur Heart J. 2012; : ehs215
        • Hamm CW
        • Bassand J-P
        • Agewall S
        • Bax J
        • Boersma E
        • Bueno H
        • et al.
        ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.
        Eur Heart J. 2011; 32: 2999-3054
        • Fihn SD
        • Gardin JM
        • Abrams J
        • Berra K
        • Blankenship JC
        • Douglas PS
        • et al.
        2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.
        J Am Coll Cardiol. 2012; 60: e44-e164
        • Montalescot G
        • Sechtem U
        • Achenbach S
        • Andreotti F
        • Arden C
        • Budaj A
        • et al.
        2013 ESC guidelines on the management of stable coronary artery disease.
        Eur Heart J. 2013; 34: 2949-3003
        • Gehi AK
        • Ali S
        • Na B
        • Schiller NB
        • Whooley MA
        Inducible ischemia and the risk of recurrent cardiovascular events in outpatients with stable coronary heart disease: the heart and soul study.
        Arch Intern Med. 2008; 168: 1423-1428
        • Calhoun M
        • Cross LB
        • Cooper-DeHoff RM
        Clinical utility of β -blockers for primary and secondary prevention of coronary artery disease.
        Expert Rev Cardiovasc Ther. 2013; 11: 289-291
        • Bangalore S
        • Steg G
        • Deedwania P
        • Crowley K
        • Eagle KA
        • Goto S
        • et al.
        β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.
        JAMA. 2012; 308: 1340-1349
        • Athyros VG
        • Papageorgiou AA
        • Mercouris BR
        • Athyrou VV
        • Symeonidis AN
        • Basayannis EO
        • et al.
        Treatment with atorvastatin to the National Cholesterol Educational Program goal versus’ usual’ care in secondary coronary heart disease prevention.
        Curr Med Res Opin. 2002; 18: 220-228
        • Cleland J
        • Erhardt L
        • Hall A
        • Winter C
        • Ball S
        • Investigators AS
        Validation of primary and secondary outcomes and classification of mode of death among patients with clinical evidence of heart failure after a myocardial infarction: a report from the Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.
        J Cardiovasc Pharmacol. 1993; 22: S22-S27
        • Study TAIREA
        Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure.
        Lancet. 1993; 342: 821-828
      1. Trinomia®. Summary of Product Characteristics.

      2. Tamboli A, Todkar P, Zope P, Sayyad F. An Overview on Bioequivalence: Regulatory Consideration for Generic Drug Products. J Bioequiv Availab 2: 086-092. doi:10.4172/jbb.1000037. OMICS Publishing Group J Bioequiv Availab ISSN; 2010.

        • Warner GT
        • Perry CM
        Drugs. 2002; 62: 1381-1405
        • Neal B
        • MacMahon S
        • Chapman N
        Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials.
        Blood pressure lowering treatment trialists’ collaboration Lancet. 2000; 356: 1955-1964
        • Mancia G
        • Fagard R
        • Narkiewicz K
        • Redon J
        • Zanchetti A
        • Böhm M
        • et al.
        2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
        Blood Pres. 2013; 22: 193-278
        • Yusuf S
        • Sleight P
        • Pogue J
        • Bosch J
        • Davies R
        • Dagenais G
        Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.
        N Engl J Med. 2000; 342: 145-153
        • Dagenais GR
        • Pogue J
        • Fox K
        • Simoons ML
        • Yusuf S
        Angiotensin-convertingenzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials.
        Lancet. 2006; 368: 581-588
        • Danchin N
        • Cucherat M
        • Thuillez C
        • Durand E
        • Kadri Z
        • Steg PG
        Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
        Arch Intern Med. 2006; 166: 787-796
        • Ruggenenti P
        • Perna A
        • Gherardi G
        • Gaspari F
        • Benini R
        • Remuzzi G
        • et al.
        Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial.
        Lancet. 1998; 352: 1252-1256
        • Nawrocki JW
        • Weiss SR
        • Davidson MH
        • Sprecher DL
        • Schwartz SL
        • Lupien P-J
        • et al.
        Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.
        Arterioscler Thromb Vasc Biol. 1995; 15: 678-682
        • Stone NJ
        • Merz CNB
        • ScM F
        • Blum FCB
        • McBride FP
        • Eckel FRH
        • et al.
        2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults.
        J Am Coll Cardiol. 2014; 63: 2889-2934
        • Trialists CT
        Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins.
        Lancet. 2005; 366: 1267-1278
        • Penning-van Beest FJ
        • Termorshuizen F
        • Goettsch WG
        • Klungel OH
        • Kastelein JJ
        • Herings RM
        Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study.
        Eur Heart J. 2007; 28: 154-159
        • Dohi T
        • Miyauchi K
        • Okazaki S
        • Yokoyama T
        • Yanagisawa N
        • Tamura H
        • et al.
        Early intensive statin treatment for six months improves long-term clinical outcomes in patients with acute coronary syndrome (Extended-ESTABLISH trial): a follow-up study.
        Atherosclerosis. 2010; 210: 497-502
      3. Smith MB, Lee NJ, Haney E, Carson S. Drug class review: Hmg-coa reductase inhibitors (statins) and fixed-dose combination products containing a statin: Final report update 5. Drug Class Reviews. 2009.

        • Rabar S
        • Harker M
        • O'Flynn N
        • Wierzbicki AS
        Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance.
        BMJ. 2014; 349: g4356
        • Capone ML
        • Tacconelli S
        • Sciulli MG
        • Grana M
        • Ricciotti E
        • Minuz P
        • et al.
        Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects.
        Circulation. 2004; 109: 1468-1471
        • Taylor DW
        • Barnett HJ
        • Haynes RB
        • Ferguson GG
        • Sackett DL
        • Thorpe KE
        • et al.
        Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial.
        Lancet. 1999; 353: 2179-2184
        • Trialists’ Collaboration A
        Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
        BMJ. 2002; 324: 71-86
        • Mozaffarian D
        • Benjamin EJ
        • Go AS
        • Arnett DK
        • Blaha MJ
        • Cushman M
        • et al.
        Executive Summary: Heart Disease and Stroke Statistics—2015 Update A Report From the American Heart Association.
        Circulation. 2015; 131: 434-441
        • Van Griensven J
        • Schoemaker R
        • Cohen A
        • Luus H
        • Seibert-Grafe M
        • Röthig H-J
        Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril.
        Eur J Clin Pharmacol. 1995; 47: 513-518
        • Davidson MH
        • Robinson JG
        Lipid-lowering effects of statins: a comparative review.
        Expert Opin Pharmacother. 2006; 7: 1701-1714
        • Lennernäs H
        Clinical pharmacokinetics of atorvastatin.
        Clin Pharmacokinet. 2003; 42: 1141-1160
        • Amir LH
        • Pirotta MV
        • Raval M
        Breastfeeding: Evidence Based Guidelines for the Use of Medicines.
        Austr Family Physician. 2011; 40: 684
        • Antman EM
        • Bennett JS
        • Daugherty A
        • Furberg C
        • Roberts H
        • Taubert KA
        Use of nonsteroidal antiinflammatory drugs an update for clinicians: a scientific statement from the American Heart Association.
        Circulation. 2007; 115: 1634-1642
        • Dargan P
        • Wallace C
        • Jones A
        An evidence based flowchart to guide the management of acute salicylate (aspirin) overdose.
        Emerg Med J. 2002; 19: 206-209
        • Carré A
        • Vasmant D
        • Elmalem J
        • Thiéry P
        Tolerability of ramipril in a multicenter study of mild-to-moderate hypertension in general practice.
        J Cardiovasc Pharmacol. 1991; 18 (S1S3): S141
        • Kostis JB
        • Packer M
        • Black HR
        • Schmieder R
        • Henry D
        • Levy E
        Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial.
        Am J Hypertens. 2004; 17: 103-111
        • Newman CB
        • Palmer G
        • Silbershatz H
        • Szarek M
        Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients.
        Am J Cardiol. 2003; 92: 670-676
        • Law MR
        • Wald NJ
        • Rudnicka A
        Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.
        BMJ. 2003; 326: 1423
        • Pasternak RC
        • Smith SC
        • Bairey-Merz CN
        • Grundy SM
        • Cleeman JI
        • Lenfant C
        ACC/AHA/NHLBI clinical advisory on the use and safety of statins12.
        J Am Coll Cardiol. 2002; 40: 567-572
        • Ma T
        • Tien L
        • Fang C-L
        • Liou Y-S
        • Jong G-P
        Statins and new-onset diabetes: a retrospective longitudinal cohort study.
        Clin Therapeut. 2012; 34: 1977-1983
        • Sattar N
        • Preiss D
        • Murray HM
        • Welsh P
        • Buckley BM
        • de Craen AJ
        • et al.
        Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.
        Lancet. 2010; 375: 735-742
        • Hayden M
        • Pignone M
        • Phillips C
        • Mulrow C
        Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force.
        Ann Intern Med. 2002; 136: 161-172
        • McQuaid KR
        • Laine L
        Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials.
        Am J Med. 2006; 119: 624-638
        • Delaney JA
        • Opatrny L
        • Brophy JM
        • Suissa S
        Drug–drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding.
        Can Med Assoc J. 2007; 177: 347-351
        • Study TIP
        Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
        The Lancet. 2009; 373: 1341-1351
        • Peterson JG
        • Lauer MS
        Using aspirin and ACE inhibitors in combination: why the hullabaloo?.
        Cleveland Clin J Med. 2001; 68: 569-573
        • Harjai KJ
        • Solis S
        • Prasad A
        • Loupe J
        Use of aspirin in conjunction with angiotensin-converting enzyme inhibitors does not worsen long-term survival in heart failure.
        Int J Cardiol. 2003; 88: 207-214
        • McAlister FA
        • Ghali WA
        • Gong Y
        • Fang J
        • Armstrong PW
        • Tu JV
        Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure.
        Circulation. 2006; 113: 2572-2578
        • Tea KK
        • Yusuf S
        • Pfeffer M
        • Kober L
        • Hall A
        • Pogue J
        • et al.
        Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review.
        Lancet. 2002; 360: 1037-1043
        • Latini R
        • Tognoni G
        • Maggioni AP
        • Baigent C
        • Braunwald E
        • Chen Z-M
        • et al.
        Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients.
        J Am Coll Cardiol. 2000; 35: 1801-1807
        • Krumholz HM
        • Chen Y-T
        • Wang Y
        • Radford MJ
        Aspirin and angiotensin-converting enzyme inhibitors among elderly survivors of hospitalization for an acute myocardial infarction.
        Arch Intern Med. 2001; 161: 538-544
        • Athyros V
        • Mikhailidis D
        • Papageorgiou A
        • Bouloukos V
        • Pehlivanidis A
        • Symeonidis A
        • et al.
        Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease.
        J Hum Hypertens. 2004; 18: 781-788